Targeting Multi-Resistant Bacteria
Bioimics is a Swedish biotechnology company focusing on development of novel antibacterial compounds, ribozyme inhibitors, for the treatment of Healthcare Associated Infections.

undreds of thousands people die annually of bacterial infections acquired in hospitals and other healthcare institutions due to Multi-Resistant Bacteria. Frequent and widespread use of different types of antibiotics under decades has led to a situation where bacterial resistance has become a threat to public health all over the world.

ioimics’ goal is to develop new antibiotics targeting Multi-Resistant Bacteria. The company capitalizes on its patented pioneer findings in RNA research and screening technique.

ioimics is privately own company located in Uppsala. The first project is in early development state where the confirmation of initial hits has been concluded successfully and the project is now entering Hit Expansion stage.